Search PubMed⌕ Search

Biomedical subjects

M Younes

Publications and source records attributed to M Younes.

272 records · Page 16Linked to original sources
PubMedDate not supplied

Stratified multivariate analysis of prognostic markers in breast cancer: a preliminary report.

Published results using prognostic markers in breast cancer have been very confusing to oncologists, surgeons, and pathologists alike. As a result, there is a wide variation in opinion among oncologists about the utility of these markers in clinical practice. This study was undertaken to determine the utility of stratified multivariate survival analysis in integrating the commonly used prognostic factors into a user-friendly prognostic scheme, and its implication for treatment decision making. 300 women with invasive ductal carcinoma of the breast who were followed-up for 28-112 months (median 72 months) were entered in the study. Patients with distant metastases, those with bilateral or multifocal tumors, and special types of carcinoma were excluded. Variables included in the stratified multivariate survival analysis were estrogen receptor (ER) status, tumor size, nodal status, histological grade, number of mitotic figures per ten high power fields (MF/10HPF), and type of initial therapy. Data was subjected to Kaplan-Meier survival analysis and the log rank test for statistical significance at different steps of the analysis. Cut-off values for ER that produced a significant difference in survival varied from 9 fmol/mg protein to as high as 76 fmol/mg protein in different patient groups, and MF/10HPF varied from 6 to 21. Patients were stratified into different groups that enabled better evaluation of treatment outcome. Patients could also be combined into three groups with significantly different survival rates (p < 0.0001). Stratified multivariate survival analysis show that prognostic markers a) are interdependent, and their cut-off values vary depending on other tumor characteristics, and b) if used in a systematic way, they can be used to guide treatment decisions.

Adult↗
PubMedDate not supplied

Immunohistochemical detection of Glut3 in human tumors and normal tissues.

Malignant cells have been shown to utilize more glucose than normal cells in vitro and in vivo. Glut3 is a member of the facilitative glucose transporters family of transmembrane proteins, and its mRNA levels has been found to be elevated in human cancers, indicating that it may play a role in glucose uptake by cancer cells. Localization and extent of expression of Glut3 protein in normal and malignant human tissues is still largely unknown. We studied Glut3 expression in a series of 325 benign and malignant human tissues using standard immunoperoxidase technique. Of the normal tissues tested, Glut3 immunoreactivity was detected only in normal testis and placenta. Twelve of 14 (86%) testicular, 3 of 22 (16%) ovarian, 2 of 8 (25%) gastric, and 11 of 41 (27%) non-small cell lung carcinomas were positive for Glut3. Other carcinomas, including those of the breast and colon, were negative. Only in Glut3-positive testicular carcinomas were most tumor cells Glut3-positive. We conclude that a) Glut3 has a limited expression in normal and malignant human tissues, as determined by immunohistochemical staining, b) Glut3 may play a role in glucose uptake in a subset of carcinomas of the lung stomach and ovary, and, therefore, these tumors may have a distinct clinical behavior, and c) Glut3 may be an attractive target for monoclonal therapy or imaging of testicular germ cell tumors.

Blotting, Western↗